P0051 - The Prevalence and Association Between Non-Alcoholic Fatty Pancreas Disease and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Karla Hernandez Randich, MD¹, Andres Chaponan-Lavalle, MD¹, Dalton A. Norwood, MD², Eleazar E.. Montalvan-Sanchez, MD³, Diego Izquierdo-Veraza, MD³, Adrian Riva-Moscoso, MD¹, Eduardo Sevilla-Acosta, MD¹, Eduardo Calderon, MD⁴, Mirian Ramirez-Rojas, MLIS⁵, Gerardo Calderon, MD⁶, Renato Beas, MD^7
1Universidad Peruana de Ciencias Aplicadas, Lima, Lima, Peru; ²UAB Minority Health and Health Equity Research Center, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL; ³Indiana University School of Medicine, Indianapolis, IN; ⁴Universidad de Monterrey, Monterrey, Nuevo Leon, Mexico; ⁵Ruth Lilly Medical Library, Indiana University School of Medicine, Indianapolis, IN; ⁶Mayo Clinic, Rochester, MN; ⁷Indiana University, Indianapolis, IN

Introduction: Non-alcoholic Fatty Pancreas Disease (NAFPD), which refers to fat accumulation in the pancreas with subsequent development of pancreatic and metabolic complications, has been linked to metabolic syndrome, abnormal glucose metabolism and liver fat deposition in non-alcoholic fatty liver disease (NAFLD). The prevalence and association of NAPFD and NAFLD still remains unclear. We aimed to conduct a systematic review and meta-analysis assessing the prevalence and association of NAFPD in patients with NAFLD.

Methods: A comprehensive search of multiple databases including MEDLINE (OVID), Cochrane Library, Embase, Scopus, SciELO and Web of Science was conducted from inception to April 2023 for all published studies that reported the prevalence of NAFPD among patients with NAFLD in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Two independent reviewers extracted data. Disagreements were resolved by a third author. Pooled prevalences and pooled odds ratios (OR) were calculated after Freeman-Tukey Double Arcsine Transformation. Heterogeneity was assessed using the Higgins I2 index.

Results: Among 1520 articles identified, 163 studies were identified for full text review and 18 studies were eligible for inclusion, with perfect agreement between investigators (kappa=1.0). Eight of them were cross sectional. A total of 8933 patients with NAFLD were included in the studies (Table 1). The majority of studies were conducted in an outpatient setting and utilized Abdominal Ultrasound (US) to diagnose NAFLD and NAFPD. The overall pooled prevalence of NAFPD was noted to be 42.59% (Figure 1) with high heterogeneity (I²=98.74%). Pooled OR with 95% confidence interval (CI) for NAFPD in patients with NAFLD was 3.24 (2.07-3.06), I²=74.93% (Figure 1).

Discussion: Our meta-analysis demonstrates that NAFPD can be found in almost half of patients with NAFLD. Also, NAFLD was significantly associated with an increased risk of having NAFPD. Further studies are needed to evaluate the nature of this association and to what extent NAFPD is a consequence of NAFLD or a contributing factor. This will help elucidate mechanisms involved, complications, clinical consequences, and novel therapies for these conditions.




Disclosures:


Karla Hernandez Randich, MD¹, Andres Chaponan-Lavalle, MD¹, Dalton A. Norwood, MD², Eleazar E.. Montalvan-Sanchez, MD³, Diego Izquierdo-Veraza, MD³, Adrian Riva-Moscoso, MD¹, Eduardo Sevilla-Acosta, MD¹, Eduardo Calderon, MD⁴, Mirian Ramirez-Rojas, MLIS⁵, Gerardo Calderon, MD⁶, Renato Beas, MD⁷. P0051 - The Prevalence and Association Between Non-Alcoholic Fatty Pancreas Disease and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.